Promotility Medications – Now and in the Future

G. Karamanolis  J. Tack
Center for Gastroenterological Research, KU Leuven, Leuven, Belgium

Introduction

Gastrointestinal promotility drugs are used to stimulate, either directly or indirectly, smooth muscle contractions, leading to enhancement of gastric emptying and acceleration of small and large bowel transit. They are considered drugs of choice for the treatment of gastrointestinal functional motor disorders. Dopamine receptor antagonists, serotonergic agents acting as agonists at the \(5\)-TH\(_4\) receptor and motilin receptor agonists are the drugs currently available on the market. Novel drugs include newer types of antidopaminergic and serotonergic agents, as well as new classes of prokinetics such as CCK\(_A\) receptor antagonists and opioid receptor antagonists. The aim of the present article was to review and address the present use and efficacy of promotility drugs in the treatment of different gastrointestinal motor disorders, as well as the potential for future developments.

Dopamine Receptor Antagonists

The rationale for using antidopaminergic agents as prokinetics was based on observations that dopamine receptors are present in the gastrointestinal wall of several mammals, through which administration of dopamine causes potent inhibition of motility. Dopamine reduces lower esophageal sphincter (LES) tone, reduces gastric
The prokinetic action of domperidone may be transitory both liquid and solid gastric emptying [7]. In controlled trials were often of poor quality with heterogeneity between studies [11–13]. The efficacy of domperidone was assessed antidopaminergic properties at peripheral D₂ receptors [3–5]. The drug increases LES pressure and accelerates gastric emptying by inhibiting receptive fundic relaxation and enhancing gastroduodenal coordination. It is available in most countries of the world except for the USA. The main advantage of domperidone is that it does not cross the blood-brain barrier, and therefore extrapyramidal dystonic reactions are rare [4].

Domperidone has been studied primarily in patients with diabetic gastroparesis, in whom the drug accelerates both liquid and solid gastric emptying [7]. In controlled clinical trials, domperidone is more effective than placebo in patients with diabetic gastroparesis and in symptomatic diabetic patients with normal gastric emptying [8, 9]. The prokinetic action of domperidone may be transitory in nature. Although its effect on solid gastric emptying was lost at 6 weeks [7, 9], persistent reduction in symptom severity has been reported [9]. Domperidone is the drug of choice for patients with Parkinson’s disease with gastrointestinal symptoms secondary to gastroparesis or to dopaminergic drugs used to treat the disease [10].

For functional dyspepsia (FD), recent reviews suggest that domperidone is more effective than placebo, but the trials were often of poor quality with heterogeneity between studies [11–13]. The efficacy of domperidone was largely based on the global assessment of improvement by the investigator [11], and therefore further research to conclusively establish its place in FD therapy is needed [13]. In contrast to its action in the upper gut, domperidone has little prokinetic activity in the colon and may blunt the postprandial gastrocolonic response [14, 15].

The drug is given orally and the most common side effects relate to hyperprolactinemia, which may promote gynecomastia, galactorrhea, amenorrhea and impotence [16, 17]. Hyperprolactinemia has been described in response to D₂ receptor blockade by domperidone and seems to occur irrespective of the ability of the drug to cross the blood-brain barrier, as the pituitary is outside of this barrier. Hyperprolactinemia tends to decrease during the chronic administration of domperidone, and galactorrhea usually ceases within 1 week after discontinuation [16].

**Metoclopramide**

Metoclopramide, a substituted benzamide, is a major dopamine receptor antagonist that has been used as a prokinetic for at least 35 years. In addition to its action on D₂ receptors, metoclopramide is known to interact with serotonergic receptors. Metoclopramide has moderate partial 5-hydroxytryptamine-4 (5-HT₄) receptor agonist properties and weak 5-HT₃ receptor antagonist properties [3]. It has been suggested that the activation of 5-HT₄ receptors by metoclopramide contributes to its gastrointestinal prokinetic action by enhancing acetylcholine (Ach) release from intrinsic cholinergic motor neurons [18]. The prokinetic properties of metoclopramide are limited to the proximal gut, where it increases esophageal, fundic, and antral contractile amplitudes, stimulates gastric emptying, and improves antropyloroduodenal coordination.

Metoclopramide is approved for use in diabetic gastroparesis and for prevention of postoperative and chemotherapy-induced nausea and vomiting. A recent review on gastroparesis suggests that metoclopramide provides symptomatic relief while accelerating gastric emptying in patients with idiopathic, diabetic, and post-vagotomy gastroparesis [19]. Although its prokinetic effect may last for a short time period [20], diabetic patients with gastroparesis reported sustained symptom improvement on metoclopramide [21].

Metoclopramide most commonly is given orally, whereas intravenous administration is used for patients hospitalized with severe gastroparesis. The main limiting factor to the routine use of metoclopramide is its side effect profile. All prokinetics with central D₂ receptor antagonist properties have been found to induce extrapyramidal reactions, and these effects may restrict the use of metoclopramide in up to 30% of patients. Side effects include drowsiness, agitation, irritability, fatigue, and dystonic reactions [16]. Prolonged treatment with metoclopramide can produce Parkinson-like symptoms [22], which subside within 2–3 months following discontinuation of drug. Metoclopramide-evoked dystonic reactions occur more frequently in women than men and in children and the elderly than in adults [23]. Antagonism of hypophysal D₂ receptors may result in increased prolactin release with subsequent development of breast engorgement, lactation, and menstrual irregularity.
Levosulpiride

Levosulpiride is a benzamide derivative, which selectively inhibits D₂ receptors and also interacts with 5-HT₄ receptors, and to a lesser extent with 5-HT₃ receptors [24, 25]. It has been suggested that the serotonergic component possessed by levosulpiride may enhance its therapeutic efficacy in stimulating gastric and small bowel motility [25].

Indeed, a multicenter, double-blind, controlled study showed that levosulpiride was more effective than domperidone, metoclopramide, and placebo in patients with FD [26]. Moreover, levosulpiride was found to accelerate gastric emptying and improve gastrointestinal symptoms in patients with FD [27, 28], and in diabetic gastroparesis [29]. A recent randomized, double-masked study in patients with FD showed that levosulpiride is at least as effective as cisapride in the treatment of dysmotility-like FD [30]. Although chronic administration of levosulpiride reduced gastric sensitivity and decreased dyspeptic symptoms in patients with FD, it failed to modify gastric fundus compliance [31].

The drug is given orally and crosses the blood-brain barrier [24]. As a centrally acting antidopaminergic agent, levosulpiride associated with occurrence of extrapyramidal reactions and hyperprolactinemia.

Others

Itopride is a novel prokinetic agent that acts both as a dopamine D₂ receptor antagonist and as an acetylcholinesterase inhibitor. The threshold of itopride to promote gastrointestinal motility is higher than that of cisapride, metoclopramide and domperidone [32]. Small clinical trials showed that therapy with itopride in patients with FD and GERD resulted in good symptomatic relief, and the drug was safe and well tolerated [33–35]. A recent large-scale clinical study confirmed that itopride was significantly better than placebo for symptom control in patients with FD [36]. The drug did not cause a QT prolongation and appears to be devoid of any cardiac side effects.

Clebopride and bromopride are two other antidopaminergic prokinetics which are less widely used and are marketed only in some countries [16]. Clebopride is the antidopaminergic drug that is most associated with the occurrence of dystonic reactions [16]. Chronic treatment with this compound may be associated with reversible Parkinson-like symptoms, but also with tardive dyskinesia, which is potentially irreversible.

Alizapride is a compound that has antagonistic properties at D₂ receptors and is also considered as a prokinetic; however, it is almost exclusively used as an antiemetic drug [16].

Serotonergic Agents

Approximately 80% of total body 5-HT is found in the gut where it plays a central role in the initiation of the peristaltic reflex on enteric neurons. Therefore, 5-HT receptors are among the primary targets for promotility drugs. The main effects relevant to gastrointestinal motility are mediated via 5-HT₃, 5-HT₄ and 5-HT₁ receptors. 5-HT₄ receptor agonist induce peristaltic contraction by increasing release of Ach from excitatory neurons, whereas 5-HT₁ receptors are involved in the control of the accommodation reflex by releasing nitric oxide that relaxes the gastric fundus [37].

Cisapride

Cisapride was the first truly serotonergic drug used as prokinetic. It is a non-selective 5-HT₄ receptor agonist with partial weak 5-HT₃ antagonist effect [38]. The drug exhibits prokinetic actions in the distal esophagus, stomach, jejunum and colon and has reported efficacy for several gut functional or motor disorders.

The rationale for use of cisapride in GERD is based on its ability to increase the amplitude of esophageal contractions and the pressure of LES and to accelerate gastric emptying and oro-cecal transit [37, 39]. In patients with FD, cisapride has been used in order to reverse abnormalities that are potentially involved in FD pathophysiology. Cisapride stimulates antral and duodenal contractions, improves antrouduodenal coordination, and accelerates gastric emptying. In patients with gastroparesis, cisapride was shown to decrease symptoms, an effect that was reported to persist for up to 1 year [39–41]. In healthy volunteers, cisapride does not modify gastric compliance, but it enhances postprandial gastric relaxation [42]. These multiple actions may contribute to treatment efficacy of cisapride in FD, with a meta-analysis suggesting an overall positive, but modest, treatment effect [12]. In humans, cisapride stimulates small bowel motility [43] and decreases small bowel transit [44]. Based on studies in relatively small patient groups with this rare disorder, cisapride was reported to be effective in acute and chronic idiopathic pseudo-obstruction [45].

Cisapride has been withdrawn from most markets due to the occurrence of cardiac arrhythmias and sudden death. These effects were considered to be unrelated to the 5-HT₄ agonism but were to be due to the benzamide
structure of cisapride, which blocks cardiac human ether-
à-go-go-related gene (HERG) potassium channels and
can result in prolongation of QT interval [19, 46].

Tegaserod
Tegaserod, an aminoguanidine indole compound, is
a partial 5-HT₄ receptor agonist which can also block
5-HT₂b receptors [47]. Tegaserod has been shown to ac-
celerate orocecal transit in healthy volunteers [48]. Tega-
serod has mainly been evaluated for the treatment of con-
stipation-predominant irritable bowel syndrome (IBS).
In constipation-predominant IBS patients, tegaserod ac-
celerates transit in the small intestine and ascending co-
lon [49]. Moreover, clinical trials in constipation-pre-
dominant IBS have reported reductions in discomfort
and improvement in constipation and bloating with tega-
serod compared with placebo [50–52]. A recently pub-
lished evidence-based position statement on the manage-
ment of IBS assigned tegaserod a grade A recommenda-
tion based on the evidence available to support its use
and its ability to provide global symptom relief [53]. The
effective dose of tegaserod is 12 mg/day in two divided
doses (6 mg twice daily). The drug was significantly effec-
tive, with approximately a 10% advantage over placebo
in the intent-to-treat population and up to 14% advantage
over placebo in females and those with constipation
during the baseline run-in period. Moreover, a large, prospec-
tive, multinational placebo-controlled study established
that tegaserod was effective and well tolerated during both
first and repeated treatment in women with consti-
ption-predominant IBS [54].

Two recent multinational placebo-controlled random-
ized studies (one in Europe and another in North and
South America) in patients with chronic constipation
showed that tegaserod was also safe, well tolerated and
effective in relieving symptoms of constipation [55, 56].
Tegaserod also has a prominent prokinetic effect in the
upper gut and the drug is currently under investigation
for treatment of GERD, FD and gastroparesis. It has been
shown to increase esophageal acid clearance [57], stimu-
late interdigestive small bowel motility and postprandial
antral and intestinal motility [58], and accelerate gastric
emptying in some [48] but not all studies of healthy vol-
unteers [49]. In a preliminary report in patients with gas-
troparesis, tegaserod was shown to accelerate solid gastric
emptying in a dose-dependent fashion [59]. A recent
study, in healthy volunteers, showed that tegaserod en-
hanced gastric accommodation to a meal, indicating its
potential for the treatment in FD patients with impaired
accommodation [60]. Indeed, in FD patients with normal
gastric emptying tegaserod significantly increased meal-
induced gastric accommodation [61], and a phase 2b
study found positive effects on some dyspeptic symptoms
(improvement in early satiety and postprandial fullness)
[62].

Unlike cisapride, tegaserod has not been associated
with cardiac dysrhythmic activity, was well tolerated and
had no significant side effects [60, 63]. The most frequent
adverse effects were gastrointestinal related, such as diar-
rhea and abdominal pain, both of them mild [55, 56, 60,
63].

Renzapride
Renzapride is a novel substituted benzamide that pos-
posses both 5-HT₄ receptor full agonist [64] and 5-HT₃
receptor antagonist properties [64, 65]. Although these
properties are similar to those of cisapride, renzapride
was 10-fold less potent than cisapride in blocking HERG
potassium channels that are responsible for causing car-
diac arrhythmias [66].

Renzapride was found to cause significant dose-related
acceleration of colonic transit time, particularly ascend-
ing colonic emptying, in patients with constipation-pre-
dominant IBS [67]. Moreover, preliminary studies
showed that renzapride may improve symptoms in pa-
patients who are constipation-predominant [68, 69].

In order to assess the safety and efficacy of renzapride
in patients with constipation-predominant IBS, a place-
bo-controlled study was designed [70]. This study showed
that renzapride had a prokinetic effect, as demonstrated
by the increases in overall gastrointestinal motility, and
that this effect appeared to be dose-dependent. Moreover,
renzapride was well tolerated with lack of effect on car-
diovascular function and on prolactin levels. The most
common treatment adverse events were abdominal pain,
headache, constipation and diarrhea (reported only in
during renzapride treatment).

In addition to treating constipation, renzapride also
accelerated gastric emptying in healthy volunteers and in
a small group of diabetic patients with gastroparesis and
it may thus be useful in treating gastroparetic patients [71,
72].

Other 5-HT₄ Receptor Agonists
Second-generation 5-HT₄ receptor agonists devoid of
side effects on cardiac depolarization are currently under
investigation as an alternative to cisapride.

Mosapride is a benzaminide derivative that exhibits
both 5-HT₄ receptor agonist and 5-HT₃ receptor antago-
nist properties and is commercially available in Japan.
Mosalaprîde produced no side effects on the HERG current and should be a safe alternative to cisapride [66]. Mosalapride has been proposed for use in upper gut motility disorders and it was shown to alleviate GERD [73] and to have significant effect, comparable to those of cisapride on acid reflux parameters and esophageal motor function in patients with GERD [74]. However, a study in patients with FD showed no benefit of mosapride over placebo [75].

**Prucalopride** belongs to a new class of drugs known as benzo furancarboxamide and is a highly selective 5-HT$_4$ receptor agonist. Prucalopride has been shown to improve stool frequency and consistency and to decrease gut transit time in healthy volunteers [76, 77]. In clinical trials it has been used for treatment of chronic constipation with promising results [78–80]. The drug was shown to decrease total gut transit and to normalize stool consistency in patients with resistant constipation. Prucalopride was generally well tolerated, with mild to moderate in severity side effects. The commonest adverse effects were headache, nausea and abdominal cramps and there were no clinically relevant effects on cardiovascular parameters [78–80]. Clinical trials have been discontinued because of carcinogenicity in animals [17].

**5-HT$_1$ Receptor Agonists**

5-HT$_1$ receptors can mediate enhanced postprandial relaxation and it would be logical to try 5-HT$_1$ receptor agonists in FD. Administration of sumatriptan, a 5-HT$_1$ receptor agonist used in the treatment of migraine, relaxes the proximal stomach in healthy subjects [81]. In acute studies, subcutaneous administration of sumatriptan was shown to restore the meal-induced relaxation in patients with impaired gastric accommodation and to increase the amount of calories ingested at maximum satiety in patients with early satiety [82]. Due to its pharmacological properties, its cost, and its mode of administration, subcutaneous sumatriptan is not suitable for chronic treatment of FD. A nasal spray formulation of sumatriptan had no significant effect on proximal stomach function [83].

**Buspirone** is a non-selective 5-HT$_1$ receptor agonist, used in the treatment of panic attacks. In a placebo-controlled study in patients with FD, we confirmed that buspirone was superior to placebo in alleviating dyspeptic symptoms, and that this was associated with an enhancement of the accommodation to a meal [84].

Short-term studies in healthy volunteers using the novel 5-HT$_1$ receptor agonist R-137696 established that the drug had a dose-dependent relaxatory effect on the proximal stomach [85]. A subsequent 4-week multicenter placebo-controlled study failed to show any effect of the drug on gastric compliance and accommodation, suggesting that desensitization to the drug effect had occurred [86].

**Motilin Receptor Agonists**

Motilin is an endogenous peptide that is cyclically released during the interdigestive state, where it has been implicated in the initiation of phase III contractile activity of the migrating motor complex [87]. Motilin stimulates motility through its action at gut receptors; there is a gradient of motilin receptors from stomach to terminal ileum, with the highest density in the upper gut [88]. Agonists of motilin receptors, such as erythromycin and structurally related synthetic analogues devoid of antibacterial properties (motilides), are potent prokinetics with clinical efficacy in motility disorders [89].

**Erythromycin**

Erythromycin, a macrolide antibiotic, stimulates gut motility through a direct action at motilin receptors on smooth muscle and on enteric nerves [88–90]. Erythromycin affects the motor behavior of different gastrointestinal regions. The drug increased LES pressure by stimulation of cholinergic nerves [91]; however, in reflux disease, no significant differences in acid exposure times were observed between placebo and erythromycin [92].

Several short-term studies reported that erythromycin could stimulate gastric emptying in patients with diabetic, idiopathic, and postvagotomy gastroparesis [93–95]. Erythromycin is more potent when used intravenously, whereas orally erythromycin appears to be less effective [94, 96]. A recent meta-analysis of prokinetics used in gastroparesis reported that the effects of erythromycin on gastric emptying are greater than observed with other prokinetic drugs [13]. Regarding the treatment of symptoms in gastroparetic patients on oral erythromycin, a recent review showed that improvement was noted in only half of the patients [97]. A desensitization of the motilin receptor when using oral erythromycin in high doses for long period was suggested as a possible explanation [98]. However, we recently showed that in a setting where desensitization played no role (acute administration of erythromycin), erythromycin-enhanced gastric emptying was not associated with a beneficial effect on meal-related symptom severity in patients with FD and delayed gastric emptying [99]. These findings suggest that the therapeutic
effect of erythromycin in the treatment of FD patients with delayed gastric emptying is at best modest.

Furthermore, studies assessing the effect of erythromycin on gastric tone reported that administration of motilin or of erythromycin reduced meal-induced relaxation [100–102], thereby enhancing sensitivity to gastric distention [103]. This adverse effect of erythromycin on gastric accommodation to a meal may contribute to its overall poor symptomatic response in patients with FD. Therefore, the effect of the drug on the proximal stomach should be considered when erythromycin is used in FD patients, since it seems to be inappropriate in patients with impaired accommodation. It is important to note that the effect of erythromycin on the human fundus is a direct smooth muscle effect [100] while the effect on the antrum is neurally mediated [90]. Both effects may contribute to acceleration of gastric emptying, but the effect on the fundus may affect accommodation, sensitivity, and dyspeptic symptoms.

The effect of erythromycin on colonic transit is controversial. In healthy volunteers, erythromycin was found to reduce or not to affect the transit time of radiopaque markers in the proximal and distal colon, respectively [104, 105]. The possible prokinetic effect of erythromycin on colon was not observed in patients with IBS [106], an observation that is not surprising in view of the gradient of motilin receptors along the gut.

**ABT-229 (Alemcinal)**

ABT-229 is a novel motilin receptor agonist devoid of the antibacterial activity [107] that has been studied in clinical trials of FD and of GERD. This agent was 10–1,000 times more potent as prokinetic than erythromycin [107, 108]. It has been shown that ABT-229 accelerates gastric emptying in a dose-dependent way in healthy subjects [109]. However, the outcomes of clinical trials with ABT-229 were unequivocally disappointing with regard to symptom improvement, both in FD patients with and without delayed emptying [110]. In fact, patients receiving ABT-229 appeared to have a worse outcome. Similarly, administration of ABT-229 in patients with diabetic gastroparesis had an adverse effect and increased the severity of dyspeptic symptoms [111]. The negative outcomes of these studies may be explained by occurrence of tachyphylaxis [98, 109] or by the fact that motilide prokinetics have an adverse effect on gastric accommodation to a meal [100–103]. Thus, when selecting prokinetic drugs for clinical application, the issue of tachyphylaxis as well as effects on the proximal stomach should be considered [89].

Recent clinical studies assessed the effect of ABT-229 on acid reflux in patients with GERD, showing that the drug neither affected esophageal motility nor accelerated gastric emptying [112–114]. In one study, ABT-229 was able to slightly reduce the esophageal acid exposure over 24 h [114], while the other study failed to report any significant effect of ABT-229 on esophageal acid exposure [112, 113].

**Other Motilin Receptor Agonists**

**KC 11458** is a non-peptide motilin agonist that has a macrolide structure derived from erythromycin. KC 11548 does not possess antibiotic properties, its affinity for the motilin receptor is 10-fold higher than erythromycin and it has been shown to accelerate gastric emptying in healthy subjects [115, 116]. However, a recent clinical study evaluating the acute effects of KC 11548 on gastric emptying in patients with diabetic gastroparesis showed that the drug failed to improve emptying of either solid or liquid and did not improve symptoms when compared with placebo [117].

**GM 611 (mitemcinal)** is an erythromycin derivative that acts as an agonist at the motilin receptor [118]. It is being developed as a potential treatment for reflux esophagitis, non-ulcer dyspepsia and diabetic gastroparesis. GM-611 stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract [118]. Besides being a motilin agonist, GM-611 was shown to produce a dose-dependent sustained depolarization of rabbit duodenal smooth muscle. Depolarization appeared to be associated with activation of monovalent cation-selective channels [118].

**Cholecystokinin-1 (CCK-1) Receptor Antagonists**

Cholecystokinin (CCK) is a neuropeptide released from duodenal endocrine cells in response to a variety of nutrients, notably lipids and fatty acids, and circulating CCK inhibits gastric emptying [119]. The gastrointestinal effects of CCK are mediated by CCK-1 receptors that are localized in gut tract smooth muscles and vagal afferents [120, 121]. The role of CCK-1 receptors in regulating gut motility makes these receptors important targets for drugs that could stimulate gastric motility.

**Loxiglumide** is a CCK-1 receptor antagonist that blocks the inhibitory effects of a lipid meal on gastric motility and gastric emptying. In a magnetic resonance imaging study of gastric emptying in healthy volunteers,
Dexloxiglumide, the R-isomer of loxiglumide, has enhanced potency and selectivity for CCK-1 receptors [121]. The drug blocks CCK-1 receptors localized to gastric vagal terminals and it reverses lipid-induced delayed gastric emptying in healthy subjects [124]. In FD patients, dexloxiglumide compared to placebo decreased gastric compliance and inhibited gastric accommodation to a meal, but it also reduced dyspeptic symptoms [125]. Dexloxiglumide has also been tested in patients with constipation-predominant IBS. A phase II trial has shown that in constipated female IBS patients, dexloxiglumide significantly improved abdominal pain and discomfort compared to placebo [126]. However, a recent study evaluating the pharmacodynamic effects of dexloxiglumide on gastrointestinal transit in IBS patients failed to show a significant improvement in treating symptoms [127]. Dexloxiglumide was associated with accelerated gastric emptying, and delayed ascending colon emptying, with no significant effect on overall colonic transit in constipated IBS patients.

**μ-Opioid Receptor Antagonists**

Opiates and opioids inhibit propulsive motility and cause constipation in healthy subjects [128]. The constipating actions of μ-opioid agonists are mediated by a peripheral action in the enteric nervous system, while their analgesic effects are mediated predominately by the central nervous action [121, 129, 130]. Thus, peripherally acting μ-opioid antagonist may be able to preserve normal gut motility while producing analgesic effects.

Alvimopan is an orally-active, peripherally-restricted μ-opioid antagonist that has promising prokinetic properties [131]. In a phase II study, the drug was shown to have dose-related efficacy in the treatment of opiate bowel dysfunction [132]. Alvimopan also accelerated the time to first bowel movement in patients with chronic pain receiving opiates without inhibition of the pain-relieving effect of the opiate [130]. Alvimopan has been tested in two studies of patients undergoing abdominal surgery [133, 134]. In these studies, alvimopan accelerated recovery of gastrointestinal function, shortened the time to hospital discharge, and was well tolerated. In healthy subjects, alvimopan accelerated colonic transit [135], and this acceleration was confirmed in patients with chronic constipation [136].

**Miscellaneous Prokinetic Drugs**

Several other medications with prokinetic properties have been proposed for use in different gut motor disorders.

Z-338 (acotiamide) is a novel compound with gastroprokinetic properties, based on a mechanism of action that differs from other gastroprokinetic agents. Z-338 elicits its activity via antagonism of the inhibitory muscarinic type 1 and type 2 (M1/M2) autoreceptors. A recent phase IIa, randomized, double-blind, placebo-controlled study showed that the drug provided significantly better overall symptom relief in patients with FD, although the mechanism underlying this improvement was not shown to be related to enhancement of gastric emptying, or to decreased gastric sensitivity. The drug may have the potential to enhance impaired accommodation [137].

Leuprolide is a gonadotropin-releasing hormone analogue that has been shown to decrease symptom severity in patients with functional bowel disorders, inducing propulsive gastric and small intestinal motor activity [138]. As leuprolide induced amenorrhea and might lead to osteoporosis, its use in functional disorders should be considered carefully [17].

Ghrelin is a 28-amino-acid motilin-related peptide that was first derived from rat stomach [139]. Ghrelin is the natural ligand for the growth hormone secretagogue receptor, and animal studies revealed that it has distinct effects on gastrointestinal motility [140, 141]. Recently, we confirmed a strong stimulatory effect of ghrelin on gastric interdigestive motility in man [142]. Moreover, we have shown that acute administration of ghrelin in patients with idiopathic gastroparesis enhanced gastric emptying and improved meal-induced symptoms [143].

Gastric relaxation is partly mediated via a vagovagal reflex pathway that activates intrinsic non-adrenergic, non-cholinergic neurons [144], using nitric oxide (NO) as neurotransmitter [145]. Gastric tone is also modulated by the sympathetic nervous system [146]. Thus, drugs that modulate these pathways, such as NO donors and α-receptors, may provide tools to pharmacologically alter postprandial gastric relaxation. Acute studies in patients with FD have shown some benefit of glycerin nitrate [147]. The drug improved proximal stomach accommodation to a meal and alleviated dyspeptic symptoms, but prolonged use is generally associated with undesirable
vascular side effects due to the lack of specificity. **Sildenafil** blocks phosphodiesterase type 5, which degrades NO-stimulated 3’,5’-cyclic monophosphate (cGMP), thereby relaxing smooth muscle in various organs. Acute pretreatment with sildenafil also relaxed the proximal stomach [148] and trials evaluating phosphodiesterase inhibitors in FD seem warranted. **Clonidine**, an α2-receptor agonist, increased gastric compliance, relaxed the stomach, and reduced gastric sensation in healthy subjects [149]. Acute administration of clonidine was found to decrease meal-induced symptoms in FD [150]. Reports about the effects of clonidine on gastric emptying are inconclusive. In healthy volunteers, clonidine had no significant effect on the effect of clonidine on gastric emptying in patients with diabetic gastroparesis, clonidine treatment was associated with acceleration of gastric emptying [152].

**Conclusion**

Currently available agents for treatment of gastrointestinal motor disorders include several major classes, such as antidopaminergic agents, serotonergic agents, and motilin-receptor agonists. Due to moderate prokinetic effects, poor symptomatic responses and the presence of adverse effects, there is a clear need for new classes of prokinetics. Several other prokinetic drugs, with mixed or novel pharmacological profiles, are under development or under investigation. However, the lack of insight into the pathophysiology of motor disorders creates major difficulties in selecting candidate therapeutic agents and in designing appropriate studies to investigate their therapeutic potential. Moreover, the pathophysiological heterogeneity of gastrointestinal functional disorders undoubtedly has a negative impact on the use of a single drug class for treating subsets of patients with different underlying pathophysiological abnormalities. Therefore, large-scale comparative clinical trials for both old and new classes of prokinetics are awaited in order to assess their dose, efficacy and safety. As gastrointestinal motor disorders are chronic, relapsing, and remitting disorders, it seems desirable that studies with candidate prokinetic drugs establish a long-term efficacy and not only short-term effects on gastrointestinal functions.

**References**

Promotility Medications – Now and in the Future

Potet F, Bouyssou T, Escande D, Baro I: Gastroduodenal prokinetic drugs have different affinity for the human cardiac human ether-a-go-go K\(^+\) channel. J Pharmacol Exp Ther 2001; 299:1007–1012.


Coremans G, Kertens R, Depoortere I, Stevens MA: Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82–89.


Promotility Medications – Now and in the Future


